Mahmee raised $9.2 million in Series A funding led by Goldman Sachs Asset Management. The startup's CEO, Melissa Hanna, saw the raise as clear recognition of the progress Mahmee has made in tackling disparities in maternal care.
Webinar: Date: June 9, 2022 Time: 11am ET / 8am PT
Drug innovation and the product pipeline in the cardiometabolic space is lagging due to the inherent time and cost of evidence generation needed for regulatory evaluation and approvals.
There are several factors that can impact delivery success, drive up costs and potentially delay time to market. They include:
Longer trial duration
Intensive trial-related testing
Poor medication adherence
Delayed detection of key signals linked to endpoint capture
Under-representation of the patient population for whom the treatment is intended
We will also highlight how (Medable) is working to address drug development challenges and improve the patient experience in the context of clinical studies. with its best-in-class digital products geared for the cardiometabolic sector.
Modality.ai has developed a conversational AI system that replaces in-person interviews that are part of neurological assessments for a range of disorders. The startup was judged co-winner in the pharmatech category during the recent MedCity INVEST conference in Chicago.
Alan Morgan, CEO of the National Rural Health Association, says telehealth holds significant potential to save the future of rural healthcare. However, ongoing problems such as spotty broadband access, poor digital literacy and inadequate communication are preventing utilization from becoming widespread across rural communities.
The intent of Interoperability and Patient Access regulations is not to wash your hands off them. A more empowering viewpoint is that they give organizations a chance to champion the patient and make healthcare better.
The goal of implementing artificial intelligence and machine learning in clinical research is not to replace humans with digital tools but to increase their productivity.
Dry age-related macular degeneration currently has no FDA-approved treatments but the research of Clover Therapeutics has yielded two candidates. The biotech startup has made progress in the past two years under CEO Cheng Zhang and it's now revealing more details about its approach, a new corporate identity, and a Series A financing that puts it on the path to the clinic.
MedCity INVEST Digital Health will be held in collaboration with Health Wildcatters in Dallas, Texas on September 28. Want to speak on a panel or pitch how your startup is addressing employee benefits and supporting employers and employees? Apply today.
This event will bring together healthcare futurists, novel employers, payers, providers, and forward-thinking investors and entrepreneurs who support the broad transformation being spearheaded by digital health technologies.
MedCity News 611 Broadway New York, NY 10012 United States
You received this email because you are subscribed to MedCity Daily Digest from MedCity News.
Update your email preferences to choose the types of emails you receive.
No comments